Department of Social and Behavioral Sciences, School of Nursing.
Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco, CA.
Med Care. 2019 Jun;57(6):482-489. doi: 10.1097/MLR.0000000000001126.
Primary care providers are at the center of the opioid epidemic. Whether nurse practitioners (NPs) have different opioid-prescribing outcomes from physicians is not known.
To examine opioid-prescribing outcomes of Medicare beneficiaries receiving care from NPs and physicians in primary care.
We used Medicare data from 2009 to 2013 and a propensity score-weighted analysis.
Beneficiaries residing in states in which NPs are able to prescribe controlled substances without physician oversight and who did not have a cancer diagnosis, hospice care, or end-stage renal disease.
First, we measured whether beneficiaries received any opioid prescription. Second, for beneficiaries who received opioids, we measured acute (<90 d supply) and chronic (≥90 d supply) use at baseline (2009-2010) and follow-up (2012-2013). Third, we measured potential misuse of opioid prescribing using a daily morphine milligram equivalent dose of >100 mg, overlapping prescriptions of opioids >7 days, and overlapping prescriptions of opioids with benzodiazepines >7 days.
Beneficiaries managed by NPs were less likely to receive an opioid [odds ratio (OR), 0.87; P<0.001], were less likely to be acute users at baseline (OR, 0.84; P<0.001), and were more likely to receive a high daily opioid dose of morphine milligram equivalent >100 mg compared with physician-managed beneficiaries (OR, 1.11; P=0.048).
Findings suggest educational programs and clinical guidelines may require approaches tailored to different providers. Future research should examine the contributing factors of these patterns to ensure high-quality pain management and guide policy makers on NP-controlled substance-prescribing regulations.
初级保健提供者处于阿片类药物流行的中心。护士从业者 (NPs) 的阿片类药物处方结果是否与医生不同尚不清楚。
检查初级保健中接受 NPs 和医生治疗的 Medicare 受益人的阿片类药物处方结果。
我们使用了 2009 年至 2013 年的 Medicare 数据和倾向评分加权分析。
居住在允许 NPs 在没有医生监督的情况下开具受控物质处方且没有癌症诊断、临终关怀或终末期肾病的州的受益人。
首先,我们衡量受益人是否收到任何阿片类药物处方。其次,对于接受阿片类药物的受益人,我们在基线(2009-2010 年)和随访(2012-2013 年)时衡量急性(<90 天供应量)和慢性(≥90 天供应量)使用情况。第三,我们使用每日吗啡毫克当量剂量> 100 毫克、阿片类药物重叠处方> 7 天和阿片类药物与苯二氮䓬类药物重叠处方> 7 天来衡量潜在的阿片类药物处方滥用。
由 NPs 管理的受益人接受阿片类药物的可能性较低[优势比(OR),0.87;P<0.001],基线时急性使用者的可能性较低(OR,0.84;P<0.001),并且与医生管理的受益人相比,更有可能接受高剂量吗啡毫克当量> 100 毫克的每日阿片类药物剂量(OR,1.11;P=0.048)。
研究结果表明,教育计划和临床指南可能需要针对不同的提供者采用不同的方法。未来的研究应该检查这些模式的促成因素,以确保高质量的疼痛管理,并为政策制定者提供有关 NP 控制物质处方法规的指导。